NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Centessa reported financial results for the first quarter ended March 31, 2023, highlighting strong clinical momentum and a cash runway into 2026.
Centessa Pharmaceuticals reported a net loss of $50.7 million for the first quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $346.2 million as of March 31, 2023, expected to fund operations into 2026.
- Advanced registration program for SerpinPC to treat hemophilia B, enrolling subjects in PRESent-5 observational feeder study.
- Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody to treat solid tumors.
- Conducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, for narcolepsy and other sleep disorders.
- First subject dosed in Phase 1/2a clinical trial of LB101 in March.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Centessa expects to rapidly drive its pipeline forward and anticipates a lower cash burn rate for the remainder of the year. The company believes it is well positioned with a cash runway into 2026 to support multiple clinical readouts across its programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro